GLPwatch
Papers (9189)
Page 90 of 154, ranked by citation count.
- Development of 1 Month Sustained-Release Microspheres Containing Liraglutide for Type 2 Diabetes Treatment.
- Prediction of thyroid C-cell carcinogenicity after chronic administration of GLP1-R agonists in rodents.
- Liraglutide ameliorates hepatic steatosis via retinoic acid receptor-related orphan receptor α-mediated autophagy pathway.
- Differential protective effects of exenatide, an agonist of GLP-1 receptor and Piragliatin, a glucokinase activator in beta cell response to streptozotocin-induced and endoplasmic reticulum stresses.
- Effect of once-weekly dulaglutide on renal function in patients with chronic kidney disease.
- Design and Development of a New Glucagon-Like Peptide-1 Receptor Agonist to Obtain High Oral Bioavailability.
- Semaglutide treatment for obesity in teenagers: a plain language summary of the STEP TEENS research study.
- Differences in baseline characteristics between patients prescribed sitagliptin versus exenatide based on a US electronic medical record database.
- Improvements in Cardiometabolic Risk Factors by Weight Reduction: A Post Hoc Analysis of Adults With Obesity Randomly Assigned to Tirzepatide.
- Surface Adsorption-Mediated Ultrahigh Efficient Peptide Encapsulation with a Precise Ratiometric Control for Type 1 and 2 Diabetic Therapy.
- Impact of diabetes duration on achieved reductions in glycated haemoglobin, fasting plasma glucose and body weight with liraglutide treatment for up to 28 weeks: a meta-analysis of seven phase III trials.
- Once-Weekly Semaglutide in Adolescents with Obesity. Reply.
- Effects of dose escalating liraglutide from 1.2 to 1.8 mg in clinical practice: a case-control study.
- Exenatide improves hypogonadism and attenuates inflammation in diabetic mice by modulating gut microbiota.
- Design, synthesis and biological evaluation of double fatty chain-modified glucagon-like peptide-1 conjugates.
- Oral GLP-1 Analog for Type 2 Diabetes on the Horizon.
- [Effects of glucagon-like peptide-1 on liver oxidative stress, TNF-α and TGF-β1 in rats with non-alcoholic fatty liver disease].
- What will the impact be of use of tirzepatide in patients with obstructive sleep apnea (OSA)?
- Liraglutide and resveratrol alleviated cyclosporin A induced nephrotoxicity in rats through improving antioxidant status, apoptosis and pro-inflammatory markers.
- Otolaryngologic Side Effects of GLP-1 Receptor Agonists.
- Fixed-ratio combination of insulin glargine plus lixisenatide (iGlarLixi) improves ß-cell function in people with type 2 diabetes.
- Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonist dulaglutide in patients with type 2 diabetes: a systematic review and meta-analysis of 21 randomized controlled trials.
- Efficacy of incretin-based therapies in obesity-related obstructive sleep apnea: a systematic review and meta-analysis of randomized controlled trials.
- Novel GLP-1-based Medications for Type 2 Diabetes and Obesity.
- Effect of Liraglutide Treatment on Whole-body Glucose Fluxes in C-peptide-Positive Type 1 Diabetes During Hypoglycemia.
- Intranasal Exendin-4 modifies necroptosis-mediated innate immune response to combat septic encephalopathy in rats: Role of mTORC1 in immunogenic and tolerogenic cell demise.
- Effect of survodutide, a glucagon and GLP-1 receptor dual agonist, on weight loss: a meta-analysis of randomized controlled trials.
- Comparative efficacy and tolerability of currently approved incretin mimetics: A systematic analysis of placebo-controlled clinical trials.
- SGLT2 inhibitor or GLP-1 receptor agonist in type 2 diabetes?
- Glycaemic control with liraglutide: the phase 3 trial programme.
- Comparison of the efficacy of liraglutide with pioglitazone on dexamethasone induced hepatic steatosis, dyslipidemia and hyperglycaemia in albino rats.
- Tolerance Does Not Develop Toward Liraglutide's Glucose-Lowering Effect.
- Independent and combined effects of liraglutide and aerobic interval training on glycemic control and cardiac protection in diabetic cardiomyopathy rats.
- Efficacy and safety of once-weekly exenatide after switching from twice-daily exenatide in patients with type 2 diabetes.
- Impact of insulin glargine and lixisenatide on β-cell function in patients with type 2 diabetes mellitus: A randomized open-label study.
- The effect of amycretin, a unimolecular glucagon-like peptide-1 and amylin receptor agonist, on body weight and metabolic dysfunction in mice and rats.
- Achievement of glycaemic control is associated with improvements in lipid profile with iGlarLixi versus iGlar: A post hoc analysis of the LixiLan-L trial.
- Exendin‑4 reverses endothelial dysfunction in mice fed a high‑cholesterol diet by a GTP cyclohydrolase‑1/tetrahydrobiopterin pathway.
- Tirzepatide as an Insulin Sensitizer.
- Sex Differences in Obesity and Its Treatment.
- Chronic intrahypothalamic rather than subcutaneous liraglutide treatment reduces body weight gain and stimulates the melanocortin receptor system.
- Safety, tolerability and efficacy of lixisenatide as monotherapy in Japanese patients with type 2 diabetes mellitus: An open-label, multicenter study.
- Comparison of extended release GLP-1 receptor agonist therapy versus sitagliptin in the management of type 2 diabetes.
- Down the rabbit hole: reviewing the evidence for primary prevention of cardiovascular disease in people with obesity.
- Semaglutide attenuates pathological electrophysiological remodeling in diabetic cardiomyopathy via restoring Cx43 expression.
- The importance of patient-reported outcomes in type 2 diabetes: insight from the PIONEER program with oral semaglutide.
- Lilly's tirzepatide secures first approval in diabetes, paving path for dual-acting hormone mimetics.
- Changes in Heart Rate Associated with Exenatide Once Weekly: Pooled Analysis of Clinical Data in Patients with Type 2 Diabetes.
- Antigen-specific immunotherapy combined with a regenerative drug in the treatment of experimental type 1 diabetes.
- Tirzepatide for Diabetes and Obesity: A New Window to the Treatment of Non-alcoholic Steatohepatitis.
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomized, placebo-controlled phase 2 study.
- A novel protective modality against rotenone-induced Parkinson's disease: A pre-clinical study with dulaglutide.
- Liraglutide Attenuates Restenosis After Vascular Injury in Rabbits With Diabetes Via the TGF-β/Smad3 Signaling Pathway.
- Effects of exendin-4 and selenium on the expression of GLP-1R, IRS-1, and preproinsulin in the pancreas of diabetic rats.
- A cost-utility analysis of dulaglutide versus insulin glargine as third-line therapy for Type 2 diabetes in Canada.
- SAD-A Promotes Glucose-Stimulated Insulin Secretion Through Phosphorylation and Inhibition of GDIα in Male Islet β Cells.
- Weight Loss Therapies and Hypertension Benefits.
- Exenatide effects on gastric emptying rate and the glucose rate of appearance in plasma: A quantitative assessment using an integrative systems pharmacology model.
- Semaglutide: should the media slim down its enthusiasm?
- GLP-1 Receptor Agonists in Type 2 Diabetes and Beyond - New Insights 2015.